Covered recipient · General Payments record
YOUSUF A GAFFAR
Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2023 · Entire year
$139,306.68
187 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2023 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $95,719.00 | 28 |
| Consulting Fee | $24,196.00 | 8 |
| Travel and Lodging | $14,276.13 | 25 |
| Food and Beverage | $4,922.30 | 122 |
| Long term medical supply or device loan | $166.66 | 2 |
| Education | $26.59 | 2 |
By paying entity
PY2023 · entire year · sorted by reported total
Page 3 of 4; records 101–150 of 187 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
YOUSUF A GAFFAR
NPI 1891798914 · CMS profile ID 176932
Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology
DENVER, CO
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 3 of 4; records 101–150 of 187 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1891798914?year=2023&recipient=provider&page=3#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- YOUSUF A GAFFAR, NPI 1891798914, CMS profile ID 176932. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 187 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1891798914?year=2023&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
- APA 7
- IndustryPayments. (2026). YOUSUF A GAFFAR, NPI 1891798914, CMS profile ID 176932. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 187 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1891798914?year=2023&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
- Bluebook
- YOUSUF A GAFFAR, NPI 1891798914, CMS profile ID 176932, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 4; records 101–150 of 187 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1891798914?year=2023&recipient=provider&page=3#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2023
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30
187 matching records · $139,306.68 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 101–150 of 187.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Incyte Corporation | $21.77 | 06/13/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1044481147 | CMS |
| Amgen Inc. | $14.52 | 06/09/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1020700277 | CMS |
| Dendreon Pharmaceuticals LLC | $26.41 | 06/07/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1060284635 | CMS |
| AstraZeneca Pharmaceuticals LP | $20.73 | 06/06/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1016196349 | CMS |
| PFIZER INC. | $23.03 | 06/06/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1050362261 | CMS |
| E.R. Squibb & Sons, L.L.C. | $1,141.50 | 06/01/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1015626655 | CMS |
| Rigel Pharmaceuticals, Inc. | $45.32 | 05/31/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1033404789 | CMS |
| Rigel Pharmaceuticals, Inc. | $457.80 | 05/31/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1033404801 | CMS |
| Rigel Pharmaceuticals, Inc. | $60.59 | 05/31/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1033405461 | CMS |
| Rigel Pharmaceuticals, Inc. | $5,148.00 | 05/31/2023 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1033406425 | CMS |
| E.R. Squibb & Sons, L.L.C. | $4,186.00 | 05/24/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1015626601 | CMS |
| E.R. Squibb & Sons, L.L.C. | $6,849.00 | 05/24/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1015626627 | CMS |
| Merck Sharp & Dohme LLC | $36.67 | 05/22/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1048674141 | CMS |
| Janssen Biotech, Inc. | $4.01 | 05/19/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 988414501 | CMS |
| Janssen Biotech, Inc. | $35.71 | 05/19/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 988414507 | CMS |
| Janssen Biotech, Inc. | $2.09 | 05/19/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 988414525 | CMS |
| Janssen Biotech, Inc. | $2.27 | 05/19/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 988414539 | CMS |
| SOBI, INC | $3,850.00 | 05/18/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1038136755 | CMS |
| Exelixis Inc. | $1,980.00 | 05/16/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1044557109 | CMS |
| Novartis Pharmaceuticals Corporation | $26.20 | 05/16/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 992059471 | CMS |
| PharmaEssentia USA Corporation | $28.21 | 05/16/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1059314003 | CMS |
| ABBVIE INC. | $22.62 | 05/12/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 997305275 | CMS |
| SOBI, INC | $117.76 | 05/10/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1038136929 | CMS |
| SOBI, INC | $17.55 | 05/07/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1038095143 | CMS |
| Gilead Sciences, Inc. | $25.53 | 05/06/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1025618889 | CMS |
| Exelixis Inc. | $3,300.00 | 05/02/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1044549517 | CMS |
| Rigel Pharmaceuticals, Inc. | $1,755.00 | 05/02/2023 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1033406297 | CMS |
| AstraZeneca Pharmaceuticals LP | $17.80 | 04/28/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1014381166 | CMS |
| AstraZeneca Pharmaceuticals LP | $2,200.00 | 04/28/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1014491361 | CMS |
| Exelixis Inc. | $742.50 | 04/28/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1044546537 | CMS |
| AstraZeneca Pharmaceuticals LP | $300.00 | 04/27/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1014977285 | CMS |
| Exelixis Inc. | $100.31 | 04/27/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1044545987 | CMS |
| E.R. Squibb & Sons, L.L.C. | $114.02 | 04/26/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1015626625 | CMS |
| E.R. Squibb & Sons, L.L.C. | $1,288.50 | 04/26/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1015626631 | CMS |
| Amgen Inc. | $30.24 | 04/25/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1020207443 | CMS |
| AstraZeneca Pharmaceuticals LP | $3,350.00 | 04/25/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1015160639 | CMS |
| Novartis Pharmaceuticals Corporation | $19.31 | 04/24/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 992059467 | CMS |
| AstraZeneca Pharmaceuticals LP | $95.76 | 04/20/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1015336825 | CMS |
| Regeneron Healthcare Solutions, Inc. | $22.60 | 04/20/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 999179833 | CMS |
| Janssen Pharmaceuticals, Inc | $27.09 | 04/14/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 988139183 | CMS |
| AstraZeneca Pharmaceuticals LP | $125.02 | 04/13/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1015213933 | CMS |
| GlaxoSmithKline, LLC. | $34.89 | 04/11/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1002354211 | CMS |
| Exelixis Inc. | $38.97 | 04/01/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1044535895 | CMS |
| BeiGene USA, Inc. | $28.11 | 03/28/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1051182279 | CMS |
| AstraZeneca Pharmaceuticals LP | $2,200.00 | 03/27/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1014203995 | CMS |
| TAIHO ONCOLOGY, INC. | $28.90 | 03/27/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1055233431 | CMS |
| AstraZeneca Pharmaceuticals LP | $106.11 | 03/22/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1016005539 | CMS |
| E.R. Squibb & Sons, L.L.C. | $4,186.00 | 03/21/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1015626585 | CMS |
| E.R. Squibb & Sons, L.L.C. | $6,849.00 | 03/21/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1015626589 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $20.24 | 03/21/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1055389373 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2024 | Principal investigator | $148,868.48 | 17 |
| PY2023 | Principal investigator | $268,073.31 | 124 |
| PY2022 | Principal investigator | $367,079.01 | 293 |
| PY2021 | Principal investigator | $87,078.03 | 131 |
| PY2019 | Recipient | $2,074.80 | 1 |
| PY2019 | Principal investigator | $4,834.10 | 3 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2024
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
17 records in PY2024
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Janssen Research & Development, LLC | $7,391.63 | 07/01/2024 | Non-covered Recipient Entity US ONCOLOGY RESEARCH INC | A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1079013530 |
| Principal investigator 1 | SOBI, INC | $3,072.89 | 06/18/2024 | Non-covered Recipient Entity US ONCOLOGY RESEARCH, LLC | PAC203/303 | No dispute reported | 06/30/2026 | 1141328717 |
| Principal investigator 1 | Incyte Corporation | $956.00 | 04/15/2024 | Non-covered Recipient Entity MARYLAND ONCOLOGY HEMATOLOGY, P.A. | A Phase 3 Global, Multicenter, Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) | No dispute reported | 06/30/2026 | 1134700849 |
| Principal investigator 1 | Janssen Research & Development, LLC | $12,074.12 | 03/18/2024 | Non-covered Recipient Entity US ONCOLOGY RESEARCH INC | A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1079013488 |
| Principal investigator 1 | Janssen Research & Development, LLC | $12,354.44 | 03/18/2024 | Non-covered Recipient Entity US ONCOLOGY RESEARCH INC | A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1079013992 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,178.96 | 03/18/2024 | Non-covered Recipient Entity US ONCOLOGY RESEARCH INC | A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1079014376 |
| Principal investigator 1 | Janssen Research & Development, LLC | $9,810.22 | 03/18/2024 | Non-covered Recipient Entity US ONCOLOGY RESEARCH INC | A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1079014508 |
| Principal investigator 1 | Janssen Research & Development, LLC | $7,527.27 | 03/04/2024 | Non-covered Recipient Entity US ONCOLOGY RESEARCH INC | A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1079013678 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $715.32 | 02/08/2024 | Non-covered Recipient Entity MARYLAND ONCOLOGY HEMATOLOGY, PA | An open-label, multi-center, phase II platform study evaluating the efficacy and safety of NIS793 and other new investigational drug combinations with standard of care (SOC) anti-cancer therapy for the second line treatment of metastatic colorectal cancer (mCRC) | No dispute reported | 06/30/2026 | 1089697259 |
| Principal investigator 1 | Janssen Research & Development, LLC | $8,597.13 | 02/05/2024 | Non-covered Recipient Entity US ONCOLOGY RESEARCH INC | A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1079014392 |
| Principal investigator 1 | Incyte Corporation | $20.26 | 02/01/2024 | Non-covered Recipient Entity MARYLAND ONCOLOGY HEMATOLOGY, P.A. | A Phase 3 Global, Multicenter, Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) | No dispute reported | 06/30/2026 | 1134700853 |
| Principal investigator 1 | Mirati Therapeutics, Inc. | $3,710.71 | 02/01/2024 | Non-covered Recipient Entity Us Oncology Res Llc | A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients With Advanced Solid Tumors With KRAS G12C Mutation KRYSTAL-1 | No dispute reported | 06/30/2026 | 1124762998 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $50,055.73 | 01/31/2024 | Non-covered Recipient Entity THE US ONCOLOGY NETWORK | A Phase 3 Open-label, Randomised Study of Datopotamab Deruxtecan?(DatoDXd) With or Without Durvalumab Versus Investigators Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy | No dispute reported | 06/30/2026 | 1110842349 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $6,687.80 | 01/15/2024 | Non-covered Recipient Entity MARYLAND ONCOLOGY HEMATOLOGY COLUMBIA | A Phase 3 Open-label, Randomised Study of Datopotamab Deruxtecan?(DatoDXd) With or Without Durvalumab Versus Investigators Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy | No dispute reported | 06/30/2026 | 1110839928 |
| Principal investigator 1 | Incyte Corporation | $956.00 | 01/15/2024 | Non-covered Recipient Entity MARYLAND ONCOLOGY HEMATOLOGY, P.A. | A Phase 3 Global, Multicenter, Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) | No dispute reported | 06/30/2026 | 1134700851 |
| Principal investigator 2 | Mirati Therapeutics, Inc. | $17,848.00 | 01/15/2024 | Non-covered Recipient Entity Maryland Oncology Hematology, Pa | A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients With Advanced Solid Tumors With KRAS G12C Mutation KRYSTAL-1 | No dispute reported | 06/30/2026 | 1124763102 |
| Principal investigator 1 | Mirati Therapeutics, Inc. | $1,912.00 | 01/15/2024 | Non-covered Recipient Entity Maryland Oncology Hematology, Pa | KRAS DetECT: KRAS mutation Detection to Evaluate Eligibility for Clinical Trials | No dispute reported | 06/30/2026 | 1124764080 |